Because therapies targeting FAPpos (myo)fibroblasts will likely alter myocardial FAP levels, it is of importance to understand the function and pathophysiological significance of FAP deficiency in normal healthy hearts and post-MI in vivo. The gene discussed is FAP; the disease is myocardial infarction.